Treatment of Premenstrual Dysphoric Disorder

  title={Treatment of Premenstrual Dysphoric Disorder},
  author={Andrea Rapkin and Erin I. Lewis},
  journal={Women's Health},
  pages={537 - 556}
Premenstrual dysphoric disorder (PMDD) is comprised of a cluster of affective, behavioral and somatic symptoms recurring monthly during the luteal phase of the menstrual cycle. The disorder affects 3–8% of menstruating women and represents the more severe and disabling end of the spectrum of premenstrual disorders, which includes premenstrual syndrome and premenstrual aggravation of underlying affective disorder. Rigorous and specific diagnostic criteria for PMDD were specified in the… 

The pharmacotherapeutic management of premenstrual dysphoric disorder.

Given the high rates of false positives from retrospective assessments, prospective daily symptom monitoring for a minimal of two symptomatic menstrual cycles is critical to accurately confirm (or rule out) the diagnosis of PMDD.

Premenstrual syndrome: etiology, diagnosis and treatment. A mini literature review

Treatment of PMS often requires pharmacological interventions andSerotonergic antidepressants are the mainstay for improving both physical and mood symptoms, and Oral contraceptives are also effective for relieving physical symptoms.

Eating disorders in premenstrual dysphoric disorder: a neuroendocrinological pathway to the pathogenesis and treatment of binge eating

The findings lend supports to existing studies linking binge eating to hormonal changes in the mid-luteal phase of the menstrual cycle, and may help advance new treatment options for a selected, severely impaired group of females struggling with excessive appetite and binge eating due to fluctuations in ovarian activity.

Assessment of premenstrual syndrome among female students in Southeast Nigeria

Introduction: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are premenstrual disorders characterized by a cyclical pattern of severe premenstrual symptoms experienced by

Investigation of premenstrular dysphoric disorder comorbidity and related factors in patients with anxiety disorder

PMDD is common in patients followed up with a diagnosis of anxiety disorder and what is associated with PMDD is be young age as well as excessive chocolate consumption.

Exploring premenstrual dysphoric disorder (PMDD) in the work context: a qualitative study

The most common symptoms women experience at work include difficulty in concentrating, self-doubt, paranoia, fatigue, tearfulness, a heightened sensitivity to the environment and people, outbursts, and finding social interaction particularly difficult during this premenstrual “episode” phase.

Selective Serotonin Reuptake Inhibitors for Premenstrual Dysphoric Disorder

Treatments that enhance serotonergic action improve premenstrual irritability and dysphoria with a rapid onset of action, suggesting a different mechanism of action than in the treatment of depression.

A school-based survey of premenstrual dysphoric disorder-relationship with depression, anxiety, self-esteem and quality of life

Introduction: Premenstrual dysphoric disorder (PMDD) is a severe and debilitating form of Premenstrual syndrome (PMS) affecting women in their reproductive age. There is paucity of Indian research in

Assessment of N-acetylcysteine as an Alternative for the Treatment of the Premenstrual Dysphoric Disorder: A Randomized Clinical Trial

Findings of the study are in favor of NAC use for the treatment of PMDD, with larger sample size and elongated duration of treatment and follow-ups strongly recommended.



Premenstrual Dysphoric Disorder and Severe Premenstrual Syndrome in Adolescents

Premenstrual syndrome can be ameliorated by education about the nature of the disorder, improving calcium intake, performing exercise and reducing stress, but to treat severe PMS or PMDD pharmacologic therapy is usually required.

Diagnosis and treatment of premenstrual dysphoric disorder.

Patients with mild to moderate symptoms of premenstrual syndrome may benefit from nonpharmacologic interventions such as education about the disorder, lifestyle changes, and nutritional adjustments, but those who fail to respond to more conservative measures may also require pharmacologic management.

The pharmacologic management of premenstrual dysphoric disorder.

Due to the unique pathophysiology of the disorder, the selective serotonin re-uptake inhibitors can be effectively administered intermittently, with dosing limited to the luteal phase of the cycle (2 weeks prior to menses).

Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial.

Duloxetine was effective and generally well tolerated in the treatment of PMDD and significant improvements were demonstrated by secondary measures, including reduction in self-rated functional impairment and improvement in quality of life.

Update on research and treatment of premenstrual dysphoric disorder.

Evidence suggests that individual sensitivity to cyclical variations in levels of gonadal hormones may predispose certain women to experience these mood, behavioral, and somatic symptoms in the week prior to menses.

Duloxetine for premenstrual dysphoric disorder: a pilot study

Duloxetine 60 mg/day was effective in reducing PMDD symptoms and generally well tolerated and the results appeared to be strong and consistent across measures.

Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness

  • A. RapkinS. Winer
  • Psychology, Medicine
    Expert review of pharmacoeconomics & outcomes research
  • 2009
This review will focus on the epidemiology, diagnosis, treatment outcomes, quality of life and burden of illness for premenstrual disorders.

Symptomatic Improvement of Premenstrual Dysphoric Disorder With Sertraline Treatment: A Randomized Controlled Trial

Serotonin reuptake inhibitors such as sertraline are useful therapeutic options for women with premenstrual dysphoria as reflected by symptomatic improvement and change in reported functional impairment.

Pretreatment pattern of symptom expression in premenstrual dysphoric disorder.